肿瘤拒绝抗原1在肝硬化和肝癌组织中的表达及其与肝癌临床病理学特征的关系

Expression and its clinicopathological features of tumor rejective antigen 1 in human tissues of hepatocellular carcinoma and liver cirrhosis

目的 探讨肿瘤拒绝抗原1（TRA1）在肝细胞癌（HCC）和肝硬化组织中的表达水平及其与HCC临床病理学特征的关系.方法 采用RT-PCR法、Western blot和免疫组织化学法分别检测了HCC和肝硬化组织中TRA1 mRNA和蛋白的表达水平,并与HCC临床病理学特征进行相关分析.RT-PCR和Western blot结果采用单因素方差分析;免疫组织化学结果分析采用Fisher＇s确切概率法;相关性分析采用Spearman等级相关.结果 经对RT-PCR结果分析,HCC和肝硬化组织中TRA1 mRNA表达水平高于正常肝组织水平（F值分别为20.821和12.311,P值均＜0.05）.Western blot检测结果显示,HCC和肝硬化组织中TRA1蛋白表达水平也高于正常肝组织（F值分别为21.231和20.125,P值均＜0.05）.经免疫组织化学分析,TRA1蛋白在正常对照组、肝硬化组和HCC组的表达逐渐增强,阳性表达率分别为57.14%、78.95%和93.75%.其表达水平与HCC分化程度呈负相关（r=-0.4655,P＜0.01）;与HCC患者TNM分期呈正相关（r=0.5157,P＜0.01）.结论 TRA1在肝硬化和HCC中的过表达可能与肝癌的发生和发展有关,并有可能成为一个潜在的HCC早期诊断标志物;TRA1的检测有助于判断HCC的分化程度,与HBV的感染有一定关系,同时可作为判断预后的指标.

Objective To investigate the expression of tumor rejective antigen 1 in hepatocellular carcinoma （HCC） and liver cirrhosis（LC） tissues, and the relationship between clinicopathological feature and HCC. Methods The expressions of TRA1 mRNA and its protein were detected by reverse transcription polymerase chain reaction （RT-PCR） and Western blot respectively. Immunohistochemical staining was used to further examine the expression of TRA1 protein in LC, HCC and control tissues. The relationship between clinicopathological feature and HCC was analyzed. Data of RT-PCR and Western blot were analyzed by Oneway ANOVA; results of immunohistochemical staining were analyzed by Fisher＇s exact test and correlation analysis using Spearman rank correlation. Results RT-PCR data showed that the expression of TRA1 mRNA was higher in HCC and LC tissues than that in the normal liver tissues （F values were 20.821 and 12.311respectively, P 〈 0.05）. The expression of TRA1 protein in HCC and LC tissues was signifcantly higher than that in control by Western blot （F values were 21.231 and 20.125 respectively, P 〈 0.05）. The immunohistochemical data showed the expression of TRA1 protein was gradually increased in HCC group than that in the LC group and control group, and the positive expression rate of TRA1 was 57.14%, 78.95% and 93.75%respectively. The expression of TRA1 protein was negatively correlated with HCC differentiation （r =-0.4655, P = 0.0073） and positively correlated with HCC TNM staging （r = 0.5157, P = 0.0025）. Conclusion The over-expression of TRA1 in hepatocirrhosis and HCC is correlated with the formation and development of HCC. It may be a prognostic marker for the diagnosis of HCC and be associated with the degree of differentiation and HBV infection. It can be used as a marker for prognostic prediction of HCC.